Léim chuig an ábhar
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文（繁體）
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Teanga
Gach réimse
Teideal
Údar
Ábhar
Gairmuimhir
ISBN/ISSN
Clib
AIMSIGH
CASTA
Ranibizumab versus Bevacizuma...
Luaigh é seo
Seol mar théacs é seo
Seol é seo mar r-phost
Priontáil
Easpórtáil taifead
Easpórtáil chuig RefWorks
Easpórtáil chuig EndNoteWeb
Easpórtáil chuig EndNote
Buan-nasc
Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration
Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:
Chakravarthy, U
,
Harding, S
,
Rogers, C
,
Downes, S
,
Lotery, A
,
Wordsworth, S
,
Reeves, B
Formáid:
Journal article
Foilsithe / Cruthaithe:
2012
Stoc
Cur síos
Míreanna comhchosúla
Amharc foirne
Míreanna comhchosúla
Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.
de réir: Chakravarthy, U, et al.
Foilsithe / Cruthaithe: (2012)
Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial
de réir: Chakravarthy, U, et al.
Foilsithe / Cruthaithe: (2012)
Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.
de réir: Dakin, H, et al.
Foilsithe / Cruthaithe: (2014)
Bevacizumab versus ranibizumab for neovascular age-related macular degeneration:a Meta-analysis
de réir: Wen-Jie Wang, et al.
Foilsithe / Cruthaithe: (2015-02-01)
Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients
de réir: Zhe-Li Liu, et al.
Foilsithe / Cruthaithe: (2013-04-01)